Automata, the lab automation company building fully integrated, AI-ready platforms for life sciences, today announced the close of a £33 million Series C funding round led by Dimension, with participation from Danaher Ventures, Tru Arrow Partners, Octopus Ventures and Entrepreneurs First. The round also includes a strategic investment partnership with Danaher Corporation, with Murali Venkatesan Ph.D. joining the Board of Directors. Automata is a lab automation company building fully integrated, AI-ready platforms for life sciences.
While artificial intelligence has transformed computational biology, physical lab work remains constrained by manual and fragmented workflows. Automata is addressing this gap by building a reference architecture for autonomous wet labs, combining modular robotics, orchestration software and unified data infrastructure to turn physical laboratories into programmable, repeatable systems. Its platform delivers gains in experimental throughput, reproducibility and resource efficiency across pharmaceutical, biotech and advanced research environments.
Automata counts five top pharmaceutical companies among its customers, with growth driven by repeat deployments and partnerships on large-scale automation projects. The new funding will be used to scale customer deployments globally, develop the next iteration of its data and closed-loop experimentation software platform, and expand global operations across engineering, product and customer success teams.
Through its strategic investment partnership, Danaher will integrate Automata’s software with its portfolio of instruments, reagents and software, creating end-to-end solutions designed to accelerate discovery while optimising laboratory resources.
